← Leaderboards
Robert A Fenstermaker
Roswell Park Cancer Institute Corp
$911,748
Attributed
$911,748
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $230K · FY2005–07$250K$187.5K$125K$62.5K$0
'05
'06
'07
Funding mix
By agency
NIH$911,748 · 2
By mechanism
R21$911,748 · 2
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Soldano Ferrone$11,688,743
- Walter J Storkus$19,974,413
- Steven H Bernstein$2,820,683
- Protul Shrikant$4,542,208
- Jeff C Hsu$56,109
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineTumor AntigensNeoplasm /Cancer VaccineGliomaImmune Tolerance /UnresponsivenessNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer ImmunologyAutoimmunityApoptosisAntibodies, BlockingC57bl/6 MouseCell GrowthCell Growth RegulationBrain NeoplasmsBiotechnologyAntigensCerebrumCellular ImmunityCessation Of LifeChemical Structure FunctionChemotherapyChondroitin Sulfate ProteoglycanClinically RelevantBinding (Molecular Function)
Grant awards (4)
Immunotherapy for gliomas with monoclonal antibodies targeting MCSP$230,024
R21 · FY2007 · NS · contact PI
Immunotherapy for gliomas with monoclonal antibodies targeting MCSP$211,426
R21 · FY2006 · NS · contact PI
Targeting the anti-apoptotic protein survivin in glioma$225,181
R21 · FY2005 · NS
Targeting the anti-apoptotic protein survivin in glioma$245,117
R21 · FY2004 · NS